Canaccord Genuity Maintains Buy on Enovis, Lowers Price Target to $45
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Caitlin Cronin maintains Enovis (NYSE:ENOV) with a Buy and lowers the price target from $50 to $45.
Canaccord Genuity analyst Caitlin Cronin maintains Enovis (NYSE:ENOV) with a Buy and lowers the price target from $50 to $45.